Latest Annexin Pharmaceuticals News & Updates

See the latest news and media coverage for Annexin Pharmaceuticals. We track all announcements, press releases, and industry mentions in real time, all in one place.

Annexin Pharmaceuticals

Clinical-stage biotechnology company developing Annexin A5 therapeutics

annexinpharma.com

Headquarters: Stockholm, Sweden
Founded year: 2014
Company type: Public company
Number of employees: 5–10
Industry: Pharmaceuticals

Last updated Today

Latest news about Annexin Pharmaceuticals

In short: Annexin Pharmaceuticals reported positive clinical data for its ANXV candidate and completed multiple capital raises to fund the NEXUS study.

Company announcements

July 3 Annexin Pharmaceuticals

Annexin's rights issue was 98 percent subscribed

The subscription period ended on 2 July 2026, and the company will receive 19.9 MSEK before costs.

June 23 Annexin Pharmaceuticals

Annexin Pharmaceuticals reports positive data from NEXUS study in DR and RVO

Treatment with ANXV showed improved retinal perfusion and was well tolerated, supporting further development.

June 3 Annexin Pharmaceuticals

Annexin resolves a SEK 20 million rights issue, 60% secured

The issue includes an overallotment option of up to SEK 5 million to fund phase 2a study NEXUS.

April 22 Annexin Pharmaceuticals

Annexin accelerates patient recruitment in NEXUS study

Five patients treated for RVO and DR with no safety issues. Promising initial results observed. Recruitment continues.

Media coverage

July 3 Affärsvärlden

Annexin: Almost fully subscribed despite meager discount

Annexin Pharmaceuticals' rights issue of shares was subscribed to 97.9% and the company thus receives SEK 19.9 million before expenses. Emissionsguiden raises a flag.

June 23 FinanzNachrichten.de

Annexin Pharmaceuticals AB: Annexin updates on continuous promising data from the NEXUS study - demonstrating improvement of retinal perfusion in both DR and RVO

Annexin Pharmaceuticals AB announces an update on the NEXUS study key preliminary clinical findings. To date, treatment with the drug candidate ANXV has not been...

June 17 Affärsvärlden

Coverage of Annexin's rights issue begins

Annexin Pharmaceuticals' rights issue can provide the company with 20.3 million SEK before costs.

May 21 Barron's

Annexin Pharmaceuticals AB

Annexin Pharmaceuticals AB operates as a biotechnology company. It develops treatment of various cardiovascular diseases. The firm establishes and optimizes a cell line for large-scale...

Never miss news about Annexin Pharmaceuticals

Track Annexin Pharmaceuticals and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Annexin Pharmaceuticals competitors & trending companies

Browse news for competitors to Annexin Pharmaceuticals and other trending companies.